EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy
Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called “false” neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.
KeywordsGuidelines Therapy mIBG
This guideline summarises the views of the Therapy Committee of the EANM and reflects recommendations for which the EANM cannot be held responsible.
The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.
The European Association of Nuclear Medicine has approved guidelines to promote the cost-effective use of high-quality nuclear medicine procedures. These generic recommendations cannot be rigidly applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures or exclusive of other procedures reasonably directed to obtaining the same results. Advances in medicine occur at a rapid rate. The date of a guideline should always be considered in determining its current applicability.
The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.
Last amended: December 2007.
- 2.Weiland DM, Wu J, Brown LE, Manger TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I meta-iodobenzylguanidine. J Nucl Med 1980;21:349-53.Google Scholar
- 5.Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. vol 2. 2nd ed. New York: Churchill Livingstone; 1998. p. 1067-81.Google Scholar
- 7.Radiation Protection, European Commission. Radiation protection following iodine-131 therapy (Exposures due to outpatients or discharged inpatients). Radiation Protection 97.Google Scholar
- 22.MIRD Committee of Society of Nuclear Medicine. MIRD Dose Estimate Report No. 5. J Nucl Med 1975;16:587.Google Scholar